234 related articles for article (PubMed ID: 31035033)
41. Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.
Bujarski S; Udd K; Soof C; Chen H; Spektor TM; Safaie T; Li M; Stern J; Wang C; Xu N; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Regidor B; Sutanto C; Berenson JR
Target Oncol; 2021 Jul; 16(4):503-515. PubMed ID: 34097243
[TBL] [Abstract][Full Text] [Related]
42. Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma.
Wiedemann Á; Szita VR; Horváth R; Szederjesi A; Sebő A; Tóth AD; Masszi T; Varga G
Pathol Oncol Res; 2023; 29():1611171. PubMed ID: 37188125
[No Abstract] [Full Text] [Related]
43. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
Pillarisetti K; Powers G; Luistro L; Babich A; Baldwin E; Li Y; Zhang X; Mendonça M; Majewski N; Nanjunda R; Chin D; Packman K; Elsayed Y; Attar R; Gaudet F
Blood Adv; 2020 Sep; 4(18):4538-4549. PubMed ID: 32956453
[TBL] [Abstract][Full Text] [Related]
44. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma.
Rathi C; Collins J; Struemper H; Opalinska J; Jewell RC; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):851-863. PubMed ID: 34076364
[TBL] [Abstract][Full Text] [Related]
45. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Seckinger A; Delgado JA; Moser S; Moreno L; Neuber B; Grab A; Lipp S; Merino J; Prosper F; Emde M; Delon C; Latzko M; Gianotti R; Lüoend R; Murr R; Hosse RJ; Harnisch LJ; Bacac M; Fauti T; Klein C; Zabaleta A; Hillengass J; Cavalcanti-Adam EA; Ho AD; Hundemer M; San Miguel JF; Strein K; Umaña P; Hose D; Paiva B; Vu MD
Cancer Cell; 2017 Mar; 31(3):396-410. PubMed ID: 28262554
[TBL] [Abstract][Full Text] [Related]
46. B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages.
Nobari ST; Nojadeh JN; Talebi M
J Transl Med; 2022 Feb; 20(1):82. PubMed ID: 35144648
[TBL] [Abstract][Full Text] [Related]
47. Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation.
Bera TK
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33003418
[TBL] [Abstract][Full Text] [Related]
48. Soluble B-cell maturation antigen in multiple myeloma.
Costa BA; Ortiz RJ; Lesokhin AM; Richter J
Am J Hematol; 2024 Apr; 99(4):727-738. PubMed ID: 38270277
[TBL] [Abstract][Full Text] [Related]
49. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
[TBL] [Abstract][Full Text] [Related]
50. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
[TBL] [Abstract][Full Text] [Related]
51. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
Ma T; Shi J; Liu H
Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
[TBL] [Abstract][Full Text] [Related]
52. The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma.
Xu Y; Mao X; Que Y; Xu M; Li C; Almeida VDF; Wang D; Li C
BMC Cancer; 2023 Feb; 23(1):123. PubMed ID: 36750969
[TBL] [Abstract][Full Text] [Related]
53. Regulatory roles of the tumor necrosis factor receptor BCMA.
Coquery CM; Erickson LD
Crit Rev Immunol; 2012; 32(4):287-305. PubMed ID: 23237506
[TBL] [Abstract][Full Text] [Related]
54. Expression levels and patterns of B-cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent.
Sriram H; Kunjachan F; Khanka T; Gawai S; Ghogale S; Deshpande N; Girase K; Patil J; Chatterjee G; Rajpal S; Patkar NV; Bagal B; Jain H; Sengar M; Hasan SK; Khattry N; Subramanian PG; Gujral S; Tembhare PR
Cytometry B Clin Cytom; 2022 Nov; 102(6):462-470. PubMed ID: 36346307
[TBL] [Abstract][Full Text] [Related]
55. Antibody targeting of B-cell maturation antigen on malignant plasma cells.
Ryan MC; Hering M; Peckham D; McDonagh CF; Brown L; Kim KM; Meyer DL; Zabinski RF; Grewal IS; Carter PJ
Mol Cancer Ther; 2007 Nov; 6(11):3009-18. PubMed ID: 18025285
[TBL] [Abstract][Full Text] [Related]
56. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
Tai YT; Acharya C; An G; Moschetta M; Zhong MY; Feng X; Cea M; Cagnetta A; Wen K; van Eenennaam H; van Elsas A; Qiu L; Richardson P; Munshi N; Anderson KC
Blood; 2016 Jun; 127(25):3225-36. PubMed ID: 27127303
[TBL] [Abstract][Full Text] [Related]
57. B-cell maturation antigen is modified by a single N-glycan chain that modulates ligand binding and surface retention.
Huang HW; Chen CH; Lin CH; Wong CH; Lin KI
Proc Natl Acad Sci U S A; 2013 Jul; 110(27):10928-33. PubMed ID: 23776238
[TBL] [Abstract][Full Text] [Related]
58. IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma.
Fei K; Ni H; Zhu M; Kuang Z; Wu M; Wu Z; Wang F; Zhou S; Jing H; Wu W; Wu D; Bai D; Chen B
Cancer Lett; 2022 Jun; 536():215663. PubMed ID: 35381307
[TBL] [Abstract][Full Text] [Related]
59. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses
Montes de Oca R; Alavi AS; Vitali N; Bhattacharya S; Blackwell C; Patel K; Seestaller-Wehr L; Kaczynski H; Shi H; Dobrzynski E; Obert L; Tsvetkov L; Cooper DC; Jackson H; Bojczuk P; Forveille S; Kepp O; Sauvat A; Kroemer G; Creighton-Gutteridge M; Yang J; Hopson C; Yanamandra N; Shelton C; Mayes P; Opalinska J; Barnette M; Srinivasan R; Smothers J; Hoos A
Mol Cancer Ther; 2021 Oct; 20(10):1941-1955. PubMed ID: 34253590
[TBL] [Abstract][Full Text] [Related]
60. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.
Da Vià MC; Dietrich O; Truger M; Arampatzi P; Duell J; Heidemeier A; Zhou X; Danhof S; Kraus S; Chatterjee M; Meggendorfer M; Twardziok S; Goebeler ME; Topp MS; Hudecek M; Prommersberger S; Hege K; Kaiser S; Fuhr V; Weinhold N; Rosenwald A; Erhard F; Haferlach C; Einsele H; Kortüm KM; Saliba AE; Rasche L
Nat Med; 2021 Apr; 27(4):616-619. PubMed ID: 33619368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
